Accuray (NASDAQ: ARAY) and Bruker Corporation (NASDAQ:BRKR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Dividends

Bruker Corporation pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Accuray does not pay a dividend. Bruker Corporation pays out 16.0% of its earnings in the form of a dividend.

Volatility & Risk

Accuray has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Bruker Corporation has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Accuray and Bruker Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray 0 3 2 0 2.40
Bruker Corporation 2 8 3 0 2.08

Accuray presently has a consensus price target of $6.00, suggesting a potential upside of 39.53%. Bruker Corporation has a consensus price target of $26.00, suggesting a potential downside of 14.73%. Given Accuray’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Accuray is more favorable than Bruker Corporation.

Insider & Institutional Ownership

76.7% of Accuray shares are held by institutional investors. Comparatively, 65.4% of Bruker Corporation shares are held by institutional investors. 2.9% of Accuray shares are held by company insiders. Comparatively, 35.2% of Bruker Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Accuray and Bruker Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accuray -7.71% -61.62% -7.12%
Bruker Corporation 9.65% 26.66% 10.47%

Valuation & Earnings

This table compares Accuray and Bruker Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Accuray $383.41 million 0.93 $640,996.00 ($0.35) -12.29
Bruker Corporation $1.66 billion 2.91 $275.00 million $1.00 30.49

Bruker Corporation has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Bruker Corporation, indicating that it is currently the more affordable of the two stocks.

Summary

Bruker Corporation beats Accuray on 10 of the 15 factors compared between the two stocks.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. It also focuses on nanomechanical testing instruments.

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.